TP53 and cancer: GA administration specifically impaired the ability of mutant p53 to suppress hyperactivation of Wingless-type MMTV integration site family (WNT) pathway and continuous presence of GA was required to prevent the tumor-suppressive property of mutant p53 in jejunal organoids, which opened up possible preventive and therapeutic options for cancer (53).